oral glp 1 weight loss FDA Approves First-Of-Its-Kind GLP-1 For FDA Approves First Oral GLP-1

Analyzing and evaluating the prevalence and metabolic profile of lean NAFLD compared to obese NAFLD: a systemic review and meta-analysis

The combination of potent HbA1c reduction, minimal hypoglycemia risk, and cardiovascular benefit makes these agents the preferred glucose-lowering option for most patients with type 2 diabetes

Glutathione supplements are not essential for everyone

The first step is to measure cardiovascular risk more accurately, think in cumulative exposure rather than only 10-year horizons, use apoB where possible and especially where standard markers are most likely to underrepresent risk, intervene earlier when trajectory, family history, metabolic phenotype, or imaging suggest that the risk is being understated, and keep treatment burden proportional to the quality of evidence and the person in front of the doctor